Mental Health Problems Experienced by Patients with Rheumatic Diseases During COVID-19 Pandemic

Author(s): Anass Adnine, Khawla Nadiri, Ilias Soussan, Siriman Coulibaly, Khadija Berrada, Adil Najdi, Fatima E. Abourazzak*

Journal Name: Current Rheumatology Reviews

Volume 17 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Patients with rheumatic diseases are more likely to suffer from anxiety, depression and insomnia. Yet, little is known about mental health status during COVID-19 pandemic.

Objective: This study aims to measure the prevalence of mental health disorders among patients with rheumatic diseases in the era of COVID-19 pandemic and to determine potential risk factors for major symptoms of depression, anxiety, and insomnia in participants.

Methods: Participants with rheumatic diseases were asked to complete a questionnaire using a telephonic interview. Sociodemographic and rheumatic disease characteristics were recorded. Mental health status was assessed by the patient health questionnaire-9 (PHQ-9), generalized anxiety disorder (GAD)-7, and insomnia severity index (ISI) questionnaires to detect depression, anxiety and insomnia symptoms, respectively.

Results: We included 307 patients in the survey. Rheumatoid arthritis was the most frequent diagnosis (55%). Of all participants, 7.5% had known depression and 5.5% known anxiety. Mental health disorders were insomnia (34.9%), anxiety (33.2%), and depression (24.4%). Major symptoms of insomnia, anxiety, and depression were noted in respectively, 19.9%, 12.4%, and 7.8% of participants. Risk factors for major insomnia were male gender (OR= 4.36, 95% CI 2.06 to 9.25; p<0.0001), low socioeconomic status (OR= 2.64, 95% CI 1.44 - 4.83; p<0.002) and having rheumatoid arthritis (OR= 2.00, 95% CI 1.04 to 3.84; p<0.036). Major anxiety was associated with low monthly income (OR=1.79, 95% CI 1.07 to 3.01; p<0.026), and higher Numerical Rating Scale (NRS) of pain (OR=1.795, 95% CI 1.074 to 2.994 ; p<0.026). Major depression was associated with the worsening of rheumatic disease (OR=1.86, 95% CI 1.06 to 3.26; p<0.03).

Conclusion: A high frequency of undiagnosed depression, anxiety and insomnia symptoms was found in rheumatic patients. Rheumatologists should be aware of these comorbidities, especially in the era of COVID-19 pandemic.

Keywords: Mental health, anxiety, depression, insomnia, rheumatic diseases, COVID-19.

[1]
Anyfanti P, Gavriilaki E, Pyrpasopoulou A, et al. Depression, anxiety, and quality of life in a large cohort of patients with rheumatic diseases: common, yet undertreated. Clin Rheumatol 2016; 35(3): 733-9.
[http://dx.doi.org/10.1007/s10067-014-2677-0] [PMID: 24859781]
[2]
Palagini L, Tani C, Bruno RM, et al. Poor sleep quality in systemic lupus erythematosus: does it depend on depressive symptoms? Lupus 2014; 23(13): 1350-7.
[http://dx.doi.org/10.1177/0961203314540762] [PMID: 24944187]
[3]
Stipelman BA, Augustson E, McNeel T. The relationship among smoking, sleep, and chronic rheumatic conditions commonly associated with pain in the National Health Interview Survey. J Behav Med 2013; 36(5): 539-48.
[http://dx.doi.org/10.1007/s10865-012-9447-8] [PMID: 22864597]
[4]
Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52(12): 2136-48.
[http://dx.doi.org/10.1093/rheumatology/ket169] [PMID: 24003249]
[5]
Garrido-Cumbrera M, Delgado-Domínguez CJ, Gálvez-Ruiz D, Mur CB, Navarro-Compán V. Atlas Working Group. The effect of axial spondyloarthritis on mental health: results from the atlas. J Rheumatol 2019; 46(10): 1284-9.
[http://dx.doi.org/10.3899/jrheum.180868] [PMID: 30770507]
[6]
Zhao S, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther 2018; 20(1): 140.
[http://dx.doi.org/10.1186/s13075-018-1644-6] [PMID: 29996916]
[7]
Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumatol 2011; 6(6): 617-23.
[http://dx.doi.org/10.2217/ijr.11.62] [PMID: 22211138]
[8]
Löwe B, Willand L, Eich W, et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosom Med 2004; 66(3): 395-402.
[PMID: 15184703]
[9]
Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011; 50(2): 401-9.
[http://dx.doi.org/10.1093/rheumatology/keq327] [PMID: 21059675]
[10]
Hider SL, Tanveer W, Brownfield A, Mattey DL, Packham JC. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology (Oxford) 2009; 48(9): 1152-4.
[http://dx.doi.org/10.1093/rheumatology/kep170] [PMID: 19608723]
[11]
Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology (Oxford) 2013; 52(10): 1785-94.
[http://dx.doi.org/10.1093/rheumatology/kes356] [PMID: 23236191]
[12]
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160(14): 2101-7.
[http://dx.doi.org/10.1001/archinte.160.14.2101] [PMID: 10904452]
[13]
Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009; 374(9690): 609-19.
[http://dx.doi.org/10.1016/S0140-6736(09)60879-5] [PMID: 19640579]
[14]
Interian A, Ang A, Gara MA, Rodriguez MA, Vega WA. The long-term trajectory of depression among Latinos in primary care and its relationship to depression care disparities. Gen Hosp Psychiatry 2011; 33(2): 94-101.
[http://dx.doi.org/10.1016/j.genhosppsych.2010.12.001] [PMID: 21596201]
[15]
Senra H, Rogers H, Leibach G, et al. Health-related quality of life and depression in a sample of Latin American adults with rheumatoid arthritis. Int J Rheum Dis 2017; 20(11): 1684-93.
[http://dx.doi.org/10.1111/1756-185X.12412] [PMID: 25291016]
[16]
Matcham F, Norton S, Scott DL, Steer S, Hotopf M. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford) 2016; 55(2): 268-78.
[http://dx.doi.org/10.1093/rheumatology/kev306] [PMID: 26350486]
[17]
Torales J, O’Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry 2020; 66(4): 317-20.
[http://dx.doi.org/10.1177/0020764020915212] [PMID: 32233719]
[18]
Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32(10): 2016-24.
[PMID: 16206362]
[19]
Deodhar AA, Kumthekar A, Dubreuil M. Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for development. Curr Opin Rheumatol 2017; 29(4): 293-7.
[http://dx.doi.org/10.1097/BOR.0000000000000387] [PMID: 28376060]
[20]
Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012; 64(5): 640-7.
[http://dx.doi.org/10.1002/acr.21649] [PMID: 22473918]
[21]
Shaver TS, Anderson JD, Weidensaul DN, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008; 35(6): 1015-22.
[PMID: 18412311]
[22]
AlHadi AN, AlAteeq DA, Al-Sharif E, et al. An arabic translation, reliability, and validation of Patient Health Questionnaire in a Saudi sample. Ann Gen Psychiatry 2017; 16: 32.
[http://dx.doi.org/10.1186/s12991-017-0155-1]
[23]
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16(9): 606-13.
[http://dx.doi.org/10.1046/j.1525-1497.2001.016009606.x] [PMID: 11556941]
[24]
Matcham F, Ali S, Irving K, Hotopf M, Chalder T. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study. BMC Musculoskelet Disord 2016; 17: 155.
[http://dx.doi.org/10.1186/s12891-016-1011-1] [PMID: 27068100]
[25]
Sawaya H, Atoui M, Hamadeh A, Zeinoun P, Nahas Z. Adaptation and initial validation of the Patient Health Questionnaire - 9 (PHQ-9) and the Generalized Anxiety Disorder - 7 Questionnaire (GAD-7) in an Arabic speaking Lebanese psychiatric outpatient sample. Psychiatry Res 2016; 239: 245-52.
[http://dx.doi.org/10.1016/j.psychres.2016.03.030] [PMID: 27031595]
[26]
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166(10): 1092-7.
[http://dx.doi.org/10.1001/archinte.166.10.1092] [PMID: 16717171]
[27]
Suleiman KH, Yates BC. Translating the insomnia severity index into Arabic. J Nurs Scholarsh 2011; 43(1): 49-53.
[http://dx.doi.org/10.1111/j.1547-5069.2010.01374.x] [PMID: 21342424]
[28]
Morin CM. Insomnia: Psychological assessment and management. New York: Guilford Press 1993.
[29]
Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001; 2(4): 297-307.
[http://dx.doi.org/10.1016/S1389-9457(00)00065-4] [PMID: 11438246]
[30]
Pérez-García LF, Silveira LH, Moreno-Ramírez M, Loaiza-Félix J, Rivera V, Amezcua-Guerra LM. Frequency of depression and anxiety symptoms in mexican patients with rheumatic diseases determined by self-administered questionnaires adapted to the spanish language. Rev Invest Clin 2019; 71(2): 91-7.
[http://dx.doi.org/10.24875/RIC.18002698] [PMID: 31056610]
[31]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[32]
Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany N Engl. N Engl J Med 2020; 382(10): 970-1.
[http://dx.doi.org/10.1056/NEJMc2001468] [PMID: 32003551]
[33]
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020; 92(4): 441-7.
[http://dx.doi.org/10.1002/jmv.25689] [PMID: 31994742]
[34]
Wang C, Pan R, Wan X, et al. A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain Behav Immun 2020; 87: 40-8.
[http://dx.doi.org/10.1016/j.bbi.2020.04.028] [PMID: 32298802]
[35]
Wu P, Fang Y, Guan Z, et al. The psychological impact of the SARS epidemic on hospital employees in China: exposure, risk perception, and altruistic acceptance of risk. Can J Psychiatry 2009; 54(5): 302-11.
[http://dx.doi.org/10.1177/070674370905400504] [PMID: 19497162]
[36]
Michaud K, Wipfler K, Shaw Y, et al. Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. ACR Open Rheumatol 2020; 2(6): 335-43.
[http://dx.doi.org/10.1002/acr2.11148] [PMID: 32311836]
[37]
Mowbray H. In Beijing, coronavirus 2019-nCoV has created a siege mentality. BMJ 2020; 368: m516.
[http://dx.doi.org/10.1136/bmj.m516] [PMID: 32033967]
[38]
Maunder RG, Lancee WJ, Balderson KE, et al. Long-term psychological and occupational effects of providing hospital healthcare during SARS outbreak. Emerg Infect Dis 2006; 12(12): 1924-32.
[http://dx.doi.org/10.3201/eid1212.060584] [PMID: 17326946]
[39]
Sakami S, Maeda M, Maruoka T, Nakata A, Komaki G, Kawamura N. Positive coping up- and down-regulates in vitro cytokine productions from T cells dependent on stress levels. Psychother Psychosom 2004; 73(4): 243-51.
[http://dx.doi.org/10.1159/000077743] [PMID: 15184719]
[40]
Moldin SO, Scheftner WA, Rice JP, Nelson E, Knesevich MA, Akiskal H. Association between major depressive disorder and physical illness. Psychol Med 1993; 23(3): 755-61.
[http://dx.doi.org/10.1017/S0033291700025526] [PMID: 8234581]
[41]
Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being. A World Health Organization study in primary care. JAMA 1998; 280(2): 147-51.
[http://dx.doi.org/10.1001/jama.280.2.147] [PMID: 9669787]
[42]
Gureje O, Simon GE, Von Korff M. A cross-national study of the course of persistent pain in primary care. Pain 2001; 92(1-2): 195-200.
[http://dx.doi.org/10.1016/S0304-3959(00)00483-8] [PMID: 11323140]
[43]
Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 2019; 6(2): 164-73.
[http://dx.doi.org/10.1016/S2215-0366(18)30255-4] [PMID: 30366684]
[44]
Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9(11): 853-8.
[http://dx.doi.org/10.1006/cyto.1997.0238] [PMID: 9367546]
[45]
Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016; 21(12): 1696-709.
[http://dx.doi.org/10.1038/mp.2016.3] [PMID: 26903267]
[46]
Köhler CA, Freitas TH, Maes M, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 2017; 135(5): 373-87.
[http://dx.doi.org/10.1111/acps.12698] [PMID: 28122130]
[47]
Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015; 49: 206-15.
[http://dx.doi.org/10.1016/j.bbi.2015.06.001] [PMID: 26065825]
[48]
Williams LS, Jones WJ, Shen J, Robinson RL, Weinberger M, Kroenke K. Prevalence and impact of depression and pain in neurology outpatients. J Neurol Neurosurg Psychiatry 2003; 74(11): 1587-9.
[http://dx.doi.org/10.1136/jnnp.74.11.1587] [PMID: 14617727]
[49]
Wolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol 2006; 33(10): 1942-51.
[PMID: 16960928]
[50]
Urashima K, Ichinose K, Kondo H, Maeda T, Kawakami A, Ozawa H. The prevalence of insomnia and restless legs syndrome among Japanese outpatients with rheumatic disease: A cross-sectional study. PLoS One 2020; 15(3): e0230273.
[http://dx.doi.org/10.1371/journal.pone.0230273] [PMID: 32197267]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 3
Year: 2021
Published on: 27 January, 2021
Page: [303 - 311]
Pages: 9
DOI: 10.2174/1573397117666210127124544
Price: $65

Article Metrics

PDF: 424
HTML: 1